Dihydro oat alkaloid D for reduced perfume degradation

Abstract

The present invention relates to the use of dihydroavenanthramide D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof for reducing or preventing the degradation of one or more fragrances, a method for reducing or preventing the degradation of one or more fragrances, and a method for reducing or preventing the degradation of one or more fragrances, and a perfume composition comprising one or more perfumes and dihydroavenanthramide D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof, as well as to a perfume composition comprising one or more perfumes and dihydroavenanthramide D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof.

Description

Technical Field

[0001] The present invention relates to use of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salt and / or solvate for reducing or preventing the degradation of one or more spices, a method for reducing or preventing the degradation of one or more spices, and a fragrance composition comprising one or more spices and dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salt and / or solvate. Background Art

[0002] Fragrances play an important role in the cosmetics industry and are often incorporated into various cosmetic preparations. Similarly, in the pharmaceutical industry, fragrances are also used and incorporated into drug preparations.

[0003] Cosmetic and pharmaceutical preparations are sold in all regions of the world. Therefore, from their production in one location to their final application elsewhere, for example by a consumer, there is a long transportation distance that affects these preparations. Transportation and intermediate steps often involve prolonged storage of cosmetic and pharmaceutical preparations. Furthermore, varying conditions, such as temperature, constantly affect these preparations during storage and transportation.

[0004] Therefore, after their initial production, cosmetic and pharmaceutical preparations are subjected to different conditions for a long time until they reach and are applied by the final consumer.

[0005] It has been found that these conditions have a negative impact on the fragrance(s) contained in these formulations. Typically, fragrance(s) degrade into other compounds during storage and transportation. These other compounds may have no odor or a reduced odor compared to the original compound, or may even have another odor that is perceived by consumers as unpleasant.

[0006] Even though the functionality of a cosmetic or pharmaceutical preparation may still be the same as or only insignificantly inferior to its functionality immediately after production, most consumers cannot accept products with a reduced or unpleasant odor.

[0007] Therefore, after storage and transport of the formulation, its original smell may be less intense and / or may contain additional, often unpleasant, notes, which need to be avoided.

[0008] However, it is often not possible to shorten storage and transport times or to completely avoid conditions that affect the formulations.

[0009] Therefore, a solution is needed to reduce or prevent the degradation of fragrances.

[0010] Preferably, such a solution can be used in a cosmetic or pharmaceutical preparation and thus does not impair the effect to be provided by the cosmetic or pharmaceutical preparation. Advantageously, such a solution somehow promotes or increases the effect to be provided by the cosmetic or pharmaceutical preparation. Summary of the Invention

[0011] Therefore, a main object of the present invention is to provide the possibility to reduce or prevent the degradation of one or more fragrances.

[0012] The main object of the present invention is to reduce or prevent the degradation of one or more fragrances by using dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates.

[0013] The one or more fragrances are selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers.

[0014] Dihydroavenain alkaloid D is already used, for example, in cosmetic preparations. However, surprisingly, it has been found that dihydroavenain alkaloid D is able to reduce or even prevent the degradation of fragrances, in particular fragrances selected from aldehydes, alcohols, esters, ketones, or ethers. After subjecting a mixture containing fragrances to an artificial aging and fragrance degradation process, the amount of the fragrances in the presence of dihydroavenain alkaloid D is significantly higher than in the same mixture without dihydroavenain alkaloid D, or is even unaffected by the process.

[0015] This effect of dihydroavenate alkaloid D was previously unknown and therefore surprising.

[0016] Therefore, dihydroavenain alkaloid D can be used to prevent or reduce the degradation of fragrances, for example fragrances in cosmetic or pharmaceutical preparations. Therefore, when dihydroavenain alkaloid D is added, fragrances or corresponding compositions or preparations containing fragrances are less susceptible to being affected in terms of storage and transportation.

[0017] Preferably, unless otherwise stated, all characteristics and effects of dihydroavenate alkaloid D described herein apply correspondingly to its pharmaceutically or cosmetically acceptable salts and / or solvates.

[0018] Dihydroavenate alkaloid D is a compound of particular importance in the cosmetics industry. Dihydroavenate alkaloid D belongs to the family of avenate alkaloids (i.e., anthranilamides) and is also described as hydroxyphenylpropionamidobenzoic acid. Dihydroavenate alkaloid D is described by CAS number 697235-49-7 (listed by the European Chemicals Agency) and corresponds to the following chemical structure:

[0019]

[0020] Preferably, the term "dihydroavenate alkaloid D" includes compounds according to the above chemical structure as well as keto-enol tautomers and isomers thereof.

[0021] Dihydroavenatine alkaloid D has been described for use in several cosmetic applications. For example, WO 2006 / 134013 A1 describes the use of dihydroavenatine alkaloid D for alleviating itching and / or for reducing redness of the skin.

[0022] US 2006 / 089413 A1 describes that dihydroavenous alkaloid D can be used to inhibit the release of histamine from mast cells induced by substance P. In this way, itching, redness of the skin, the development of scars or allergic skin reactions can be prevented.

[0023] Preferably, the term "salt of dihydroavenate alkaloid D" as used herein refers to a pharmaceutically or cosmetically acceptable salt of dihydroavenate alkaloid D. Particularly preferably, the term refers to or includes alkali metal salts and alkaline earth metal salts of dihydroavenate alkaloid D, and particularly preferably, sodium salt or potassium salt of dihydroavenate alkaloid D and mixtures thereof.

[0024] Preferably, the term "solvate of dihydroavenate alkaloid D" as used herein refers to a pharmaceutically or cosmetically acceptable salt of dihydroavenate alkaloid D. Particularly preferably, the term refers to or includes a solvate of dihydroavenate alkaloid D in a diol.

[0025] Preferably, the term "fragrance degradation" as used herein refers to the chemical conversion of a fragrance compound into another compound (i.e., a degraded compound). Preferably, the term "fragrance degradation" as used herein refers to the oxidative conversion of the fragrance, preferably the auto-oxidation of the fragrance. Preferably, the term "another compound" as used herein also includes stereoisomers. Preferably, the term "another compound" as used herein does not include stereoisomers.

[0026] Typically, degradation of a compound (e.g., a fragrance) can be detected by measuring the amount of the compound (e.g., fragrance) at different time points. Such measurements can be performed by mass spectrometry. If the amount is reduced at a later time point (compared to an earlier time point), the compound (e.g., fragrance) is degraded.

[0027] Typically, a degraded compound (e.g., fragrance) has an olfactory profile that is different from that of the original compound (e.g., fragrance). Typically, a different olfactory profile is considered a defect in the olfactory profile. However, for some compounds (e.g., fragrance), a degraded compound (e.g., fragrance) may have a similar or equivalent olfactory profile.

[0028] Preferably, the one, two, three or more or all fragrances are selected from the group consisting of Group A.

[0029] Group A:

[0030] 2,4-Dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, cyperaldehyde, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one , (4E)-3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brazilate, and trans-2,cis-6-nonadienal, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohexylpropionate, styryl propionate, benzyl salicylate, benzyl ethyl ether, linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyperaldehyde, hydroxycitronellal, lilial and borgihon aldehydes, ionones, isomethyl ionone and methyl cedryl ketone, anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and pine Oleyl alcohol, terpenes, balsam, clary sage oil, chamomile oil, clove oil, lemon balm oil, peppermint oil, cinnamon leaf oil, lime flower oil, juniper oil, vetiver oil, frankincense oil, galbanum oil, labdanum and lavender oils, bergamot oil, dihydromyrcenol, lilial, lyral, phenylethyl alcohol, hexyl cinnamal, benzyl acetone, ambergris, ambroxan, indole, methyl dihydrojasmonate, sandelice, lemon oil, tangerine oil, orange oil, galbanum esters, cyclovertal, lavender oil, clary sage essential oil, damascena, bourbon geranium essential oil, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, rose oxide, romillat, irotyl, floramate, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, geranium acid, decanoic acid and its methyl esters, ethyl esters, l-hexen-3-one, l-hepten-3-one, 1-octene-3-one, l-nonen-3-one, l-decen-3-one, octalactone, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 2-ethyl-l-butene, 2-ethyl-l-pentene, 2-ethyl-l-hexene, 2-ethyl-l-heptene, 2-ethyl-l-octene, cis-3-methyl-2-pentene, cis-3-methyl-2-hexene, cis-3-methyl-2-heptene, cis-3-methyl 2-octene, cis-3-methyl-2-nonene, trans-3-methyl-2-pentene, trans-3-methyl-2-hexene, trans-3-methyl-2-heptene, trans-3-methyl-2-octene, trans-3-methyl-2-nonene, cis-2-hexene, cis-2-heptene, cis-2-octene, cis-2-nonene, cis-2-decene, trans-2-hexene, trans-2-heptene, trans-2-octene, trans-2-nonene, trans-2-decene, cis-3-hexene, cis-3-heptene, cis-3-octene, cis-3-nonene, cis-3-decene, trans-3-hexene, trans-3-heptene, trans-3-octene, trans-3-nonene, trans-3-decene.

[0031] It is particularly preferred that the one, two, three or more or all fragrances are selected from the group consisting of Group B.

[0032] Group B:

[0033] 2,4-Dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, cyperaldehyde, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one, (4E) -3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brassate, and trans-2,cis-6-nonadienal.

[0034] It is particularly preferred that the one, two, three or more or all fragrances are selected from the group consisting of Group C.

[0035] Group C:

[0036] 2,4-Dimethylcyclohex-3-ene-1-carbaldehyde, linalool, linalyl acetate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, cyperaldehyde, anisaldehyde, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin.

[0037] Preferably, the compounds listed above are described by the following names or corresponding INCI names and CAS numbers. Preferably, the CAS numbers are those listed by CAS Common Chemistry (https: / / commonchemistry.cas.org / ).

[0038]

[0039]

[0040]

[0041] The surprising effects of dihydroavenain alkaloid D described herein are particularly advantageous for stabilizing one or more fragrances in fragrance compositions. Thus, dihydroavenain alkaloid D can be used to prevent or reduce the degradation of fragrances, such as those in cosmetic or pharmaceutical formulations. Consequently, when dihydroavenain alkaloid D is added, fragrances, or corresponding compositions or formulations containing fragrances, are less susceptible to degradation during storage and transportation.

[0042] Therefore, it is preferred in the use according to the present invention to reduce or prevent degradation in a fragrance composition, preferably a fragrance composition comprising one or more fragrances.

[0043] It is preferred in the use according to the present invention that degradation in a fragrance composition comprising one, two, three or more or all fragrances selected from the group consisting of Group A is reduced or prevented.

[0044] It is preferred in the use according to the present invention that degradation in a fragrance composition comprising one, two, three or more or all fragrances selected from the group consisting of Group B is reduced or prevented.

[0045] It is preferred in the use according to the present invention that degradation in a fragrance composition comprising one, two, three or more or all fragrances selected from the group consisting of Group C is reduced or prevented.

[0046] Furthermore, it is preferred in the use according to the invention to reduce or prevent degradation in cosmetic or pharmaceutical preparations, preferably in cosmetic or pharmaceutical preparations comprising one or more fragrances.

[0047] In the use according to the invention, it is preferred to reduce or prevent degradation in cosmetic or pharmaceutical preparations comprising one, two, three or more or all fragrances selected from the group consisting of group A.

[0048] In the use according to the invention, it is preferred to reduce or prevent degradation in cosmetic or pharmaceutical preparations comprising one, two, three or more or all fragrances selected from the group consisting of group B.

[0049] In the use according to the invention, it is preferred to reduce or prevent degradation in cosmetic or pharmaceutical preparations comprising one, two, three or more or all fragrances selected from the group consisting of group C.

[0050] The descriptions herein of the fragrance compositions, in particular with regard to the uses and methods of the invention, apply correspondingly to the cosmetic or pharmaceutical formulations, as applicable.

[0051] As described herein, dihydroavenate alkaloid D can prevent or reduce the degradation of fragrance(s), wherein the degraded fragrances typically provide a different, often impaired, olfactory impression. Thus, dihydroavenate alkaloid D is able to stabilize the olfactory impression of fragrance compositions.

[0052] This effect of dihydroavenate alkaloid D was not known and is surprising since dihydroavenate alkaloid D itself can, under certain conditions, provide an unpleasant glue-like olfactory impression.

[0053] Preferably, the term "stable olfactory impression" as used herein describes that the olfactory impression of a composition does not change or does not change significantly when, for example, the compositions are compared at different points in time. Preferably, the term "stable olfactory impression" as used herein describes that the intensity of the olfactory impression of a composition does not decrease or does not decrease significantly when, for example, the compositions are compared at different points in time.

[0054] Therefore, it is preferred in the use according to the invention that the olfactory impression of the fragrance composition or the cosmetic preparation or the pharmaceutical preparation is stabilized.

[0055] Preferably, a reduction in the intensity of the olfactory impression is reduced or prevented.

[0056] Preferably, the term "reducing or preventing a decrease in the intensity of the olfactory impression" refers to a comparison of two fragrance compositions or cosmetic or pharmaceutical preparations that differ only in that one of the compositions contains dihydroavenate alkaloid D. The two compositions or preparations are stored and subsequently analyzed. In this case, the decrease in the intensity of the olfactory impression is reduced or prevented such that the decrease observed in the composition or preparation containing dihydroavenate alkaloid D is less than the decrease observed in the composition or preparation not containing dihydroavenate alkaloid D.

[0057] Whether the olfactory impression has been altered (e.g., stabilized) can be determined by a trained panel evaluating olfactory impressions, for example, by evaluating olfactory descriptors on a numerical scale, as is well known to those skilled in the art. For example, a composition is produced and stored for a certain period of time. After storage, the same composition is produced again, and the newly produced composition and the stored composition are compared by olfactory evaluation.

[0058] Preferably, the olfactory impression is stable for at least 2 weeks, preferably at least 4 weeks, preferably at least 6 weeks, preferably at least 8 weeks, preferably at least 10 weeks, preferably at least 12 weeks, preferably at least 4 months, preferably at least 5 months, preferably at least 6 months, preferably at least 7 months, preferably at least 8 months, preferably at least 9 months, preferably at least 10 months, preferably at least 11 months, preferably at least 12 months, preferably at least 15 months, preferably at least 18 months, preferably at least 24 months.

[0059] It is preferred that the temperature of the e.g. composition does not exceed 70°C, preferably 65°C, preferably 60°C, preferably 55°C, preferably 50°C, preferably 45°C, preferably 40°C, preferably 35°C, preferably 30°C during the time when the olfactory impression of the composition is stable.

[0060] In the use according to the present invention, it is preferred that the amount of dihydroavenate alkaloid D and / or pharmaceutically or cosmetically acceptable salts and / or solvates thereof in the fragrance composition is in the range of 0.0005 wt.-% to 25 wt.-%, preferably in the range of 0.00075 wt.-% to 22.5 wt.-%, preferably in the range of 0.001 wt.-% to 20 wt.-%, preferably in the range of 0.0025 wt.-% to 17.5 wt.-%, preferably in the range of 0.005 wt.-% to 15 wt.-%, preferably in the range of 0.0075 wt.-% to 12.5 wt.-%, preferably in the range of 0.01 wt.-% to 10 wt.-%, preferably in the range of 0.025 wt.-% to 7.5 wt.-%, preferably in the range of 0.05 wt.-% to 5 wt.-%, based on the total weight of the fragrance composition.

[0061] In the use according to the invention, it is preferred that the amount of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates in the cosmetic or pharmaceutical preparation is in the range of 0.0001 wt.-% to 10 wt.-%, preferably in the range of 0.0005 wt.-% to 5 wt.-%, preferably in the range of 0.00075 wt.-% to 2.5 wt.-%, preferably in the range of 0.001 wt.-% to 1 wt.-%, preferably in the range of 0.0025 wt.-% to 0.5, preferably in the range of 0.005 wt.-% to 0.2 wt.-%, preferably in the range of 0.01 wt.-% to 0.1 wt.-%, based on the total weight of the preparation.

[0062] In the use according to the present invention, it is preferred that the weight ratio of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates to fragrance(s) in the fragrance composition, cosmetic preparation or pharmaceutical preparation is in the range of 500:1 to 1:30,000, preferably in the range of 250:1 to 1:10,000, further preferably in the range of 100:1 to 1:1,000, particularly preferably in the range of 10:1 to 1:100, especially preferably in the range of 5:1 to 1:5, even further preferably in the range of 2:1 to 1:2, more preferably in the range of 1.5:1 to 1:1.5.

[0063] Preferably, to determine the amount of dihydroavenain D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates in the composition or formulation, the total weight of dihydroavenain D and its salts and solvates in the composition or formulation is taken into account. In the event that one of the above substances is not present in the composition or formulation, its weight is considered to be 0 g.

[0064] Preferably, the amount of fragrance(s) in the composition is in the range of 50 wt.-% to 99 wt.-%, preferably 60 wt.-% to 97.5 wt.-%, particularly preferably 70 wt.-% to 95 wt.-%, further preferably 75 wt.-% to 92.5 wt.-%, especially preferably 80 wt.-% to 90 wt.-%, based on the total weight of the composition.

[0065] Preferably, the amount of fragrance(s) in the cosmetic or pharmaceutical preparation is in the range of 0.001 wt.-% to 3 wt.-%, preferably 0.005 wt.-% to 2 wt.-%, particularly preferably 0.01 wt.-% to 1.75 wt.-%, further preferably 0.05 wt.-% to 1.5 wt.-%, based on the total weight of the cosmetic or pharmaceutical preparation.

[0066] Preferably, the term "amount of (multiple) spices" refers to the amount selected from the group consisting of Group A,

[0067] Preferably selected from the group consisting of Group B,

[0068] Preferably, a fragrance selected from the group consisting of Group C,

[0069] It is preferred that the total weight of all these spices is taken into account to determine the amount. In the event that a spice is not present in the mixture, its weight is considered to be 0 g.

[0070] The present invention further relates to a method for reducing or preventing the degradation of one or more flavorants, comprising the steps of i) selecting one or more flavorants, the degradation of which is to be reduced or prevented,

[0071] wherein the one, two, three or more or all fragrances are selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers,

[0072] ii) providing the fragrance selected in step i)

[0073] iii) providing dihydroavenous alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates

[0074] iv) mixing the components provided in steps ii) and iii).

[0075] What was said herein with respect to the use according to the invention applies correspondingly to the method according to the invention, in particular with respect to preferred features.

[0076] Preferably, the term "selecting one or more flavourants" in step i) refers to identifying one or more flavourants.

[0077] Preferably, the step of providing dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salt and / or solvate in step iii) of the method of the present invention refers to providing dihydroavenate alkaloid D or its pharmaceutically or cosmetically acceptable salt or solvate, or a combination thereof. Such combinations include combinations of the aforementioned alternatives, but also include several possible combinations of a single alternative (as well as combinations of the aforementioned substances). For example, such combinations include providing dihydroavenate alkaloid D and its pharmaceutically or cosmetically acceptable salt, but also include providing two different pharmaceutically or cosmetically acceptable salts of dihydroavenate D.

[0078] Additionally or alternatively, the step of providing dihydroavenate alkaloid D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof may refer to providing a composition comprising providing dihydroavenate alkaloid D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof, or a combination thereof.

[0079] In the process of the present invention it is preferred that the one, two, three or more or all of the fragrances selected in step i) are selected from the group consisting of Group A.

[0080] In the process of the present invention it is preferred that the one, two, three or more or all of the fragrances selected in step i) are selected from the group consisting of Group B.

[0081] In the process of the present invention it is preferred that the one, two, three or more or all of the fragrances selected in step i) are selected from the group consisting of Group C.

[0082] The invention further relates to a method for stabilizing the olfactory impression of a fragrance composition or a cosmetic preparation or a pharmaceutical preparation,

[0083] wherein the fragrance composition or cosmetic preparation or pharmaceutical preparation comprises one, two, three or more or all fragrances selected from the group consisting of Group A,

[0084] The method comprises the following steps

[0085] a) selecting a fragrance composition or a cosmetic preparation or a pharmaceutical preparation, the degradation of which is to be reduced or prevented,

[0086] b) providing the fragrance composition or cosmetic preparation or pharmaceutical preparation selected in step a),

[0087] c) providing dihydroavenous alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates,

[0088] d) mixing the fragrance composition or cosmetic preparation or pharmaceutical preparation provided in step b) with the dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salt and / or solvate provided in step c).

[0089] Preferably, the term "selecting one or more flavours" in step a) means identifying one or more flavours.

[0090] Preferably, the step of providing dihydroavenate alkaloid D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof in step c) of the method of the present invention refers to providing dihydroavenate alkaloid D or a pharmaceutically or cosmetically acceptable salt or solvate thereof, or a combination thereof. Such combinations include combinations of the aforementioned alternatives, but also include several possible combinations of a single alternative (as well as combinations of the aforementioned substances). For example, such combinations include providing dihydroavenate alkaloid D and a pharmaceutically or cosmetically acceptable salt thereof, but also include providing two different pharmaceutically or cosmetically acceptable salts of dihydroavenate D.

[0091] Additionally or alternatively, the step of providing dihydroavenate alkaloid D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof may refer to providing a composition comprising providing dihydroavenate alkaloid D and / or a pharmaceutically or cosmetically acceptable salt and / or solvate thereof, or a combination thereof.

[0092] In the method of the present invention, it is preferred that the fragrance composition or cosmetic preparation or pharmaceutical preparation comprises a compound selected from the group consisting of Group B,

[0093] One, two, three or more or all flavors selected from the group consisting of Group C are preferred.

[0094] Preferably, the composition obtained in step iv) or respectively d) of the process of the present invention is a fragrance composition as described herein. The contents described herein regarding fragrance compositions, in particular preferred features, apply accordingly to the fragrance composition obtained in step iv) or respectively d) of the process of the present invention.

[0095] Preferably, the composition obtained in step iv) or respectively d) of the method according to the invention is a cosmetic or pharmaceutical preparation as described herein. The contents described herein regarding the cosmetic or pharmaceutical preparation, in particular the preferred features, apply accordingly to the cosmetic or pharmaceutical preparation obtained in step iv) or respectively d) of the method according to the invention.

[0096] It is preferred in the process according to the present invention that the amount of dihydroavenate alkaloid D and / or pharmaceutically or cosmetically acceptable salts and / or solvates thereof in the composition obtained in step iv) or respectively d) of the process according to the present invention is in the range of 0.0005 to 25 wt.-%, preferably in the range of 0.00075 to 22.5 wt.-%, preferably in the range of 0.001 to 20 wt.-%, preferably in the range of 0.0025 to 17.5 wt.-%, preferably in the range of 0.005 to 15 wt.-%, preferably in the range of 0.0075 to 12.5 wt.-%, preferably in the range of 0.01 to 10 wt.-%, preferably in the range of 0.025 to 7.5 wt.-%, preferably in the range of 0.05 to 5 wt.-%, based on the total weight of the composition. Preferably, the composition is a fragrance composition.

[0097] In the process according to the invention, it is preferred that the amount of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates in the composition obtained in step iv) or respectively d) of the process according to the invention is in the range of 0.0001 wt.-% to 10 wt.-%, preferably in the range of 0.0005 wt.-% to 5 wt.-%, preferably in the range of 0.00075 wt.-% to 2.5 wt.-%, preferably in the range of 0.001 wt.-% to 1 wt.-%, preferably in the range of 0.0025 wt.-% to 0.5, preferably in the range of 0.005 wt.-% to 0.2 wt.-%, preferably in the range of 0.01 wt.-% to 0.1 wt.-%, based on the total weight of the composition. Preferably, the composition is a perfume, cosmetic or pharmaceutical preparation.

[0098] In the process according to the invention, it is preferred that the weight ratio of dihydroavenate alkaloid D and / or pharmaceutically or cosmetically acceptable salts and / or solvates thereof to fragrance(s) in the composition obtained in step iv) or respectively d) of the process according to the invention is in the range of 500:1 to 1:30,000, preferably in the range of 250:1 to 1:10,000, further preferably in the range of 100:1 to 1:1,000, particularly preferably in the range of 10:1 to 1:100, especially preferably in the range of 5:1 to 1:5, even further preferably in the range of 2:1 to 1:2, more preferably in the range of 1.5:1 to 1:1.5.

[0099] Preferably, the amount of fragrance(s) in the composition obtained in step iv) or, respectively, d) of the process according to the invention is in the range of 50 to 99 wt.%, preferably 60 to 97.5 wt.%, particularly preferably 70 to 95 wt.%, further preferably 75 to 92.5 wt.%, and especially preferably 80 to 90 wt.%, based on the total weight of the composition. Preferably, the composition is a fragrance composition.

[0100] Preferably, the amount of fragrance(s) in the composition obtained in step iv) or, respectively, d) of the process according to the invention is in the range of 0.001 to 3 wt.%, preferably 0.005 to 2 wt.%, particularly preferably 0.01 to 1.75 wt.%, further preferably 0.05 to 1.5 wt.%, based on the total weight of the composition. Preferably, the composition is a fragrance, cosmetic or pharmaceutical preparation.

[0101] Preferably, to determine the amount of dihydroavenain D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates in the composition or formulation, the total weight of dihydroavenain D and its salts and solvates in the composition or formulation is taken into account. In the event that one of the above substances is not present in the composition or formulation, its weight is considered to be 0 g.

[0102] Preferably, the term "amount of (multiple) spices" refers to the amount selected from the group consisting of Group A,

[0103] Preferably selected from the group consisting of Group B,

[0104] Preferably, a fragrance selected from the group consisting of Group C,

[0105] It is preferred that the total weight of all these spices is taken into account to determine the amount. In the event that a spice is not present in the mixture, its weight is considered to be 0 g.

[0106] The present invention further relates to a fragrance composition comprising

[0107] a) one or more fragrances selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers, and

[0108] b) dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates,

[0109] wherein the peroxide value of the flavor composition is at least 0.25 mmol / L, preferably at least 0.5 mmol / L, based on the total amount of the flavor composition;

[0110] And wherein the peroxide value of the fragrance composition is at most 70%, preferably at most 65%, further preferably at most 60%, particularly preferably at most 55% of the peroxide value of the same composition without component b).

[0111] The peroxide value preferably describes the amount of peroxide per 1 litre of the composition.Peroxides are compounds with the structure ROOR, where R is any element.

[0112] Typically, when fragrances degrade, oxidation processes are involved or cause the degradation. Typically, fragrances degrade by auto-oxidation, which preferably refers to the gradual degradation of organic compounds by oxidation in air at ambient temperature (e.g., in the range of 20°C to 30°C).

[0113] Thus, the peroxide value indicates the extent of degradation that has occurred in the composition.

[0114] Surprisingly, it was found that the addition of dihydroavenain alkaloid D reduced the peroxide value in the flavor composition to about 50% compared to the same composition without dihydroavenain alkaloid D. Thus, dihydroavenain alkaloid D prevents or reduces the degradation of flavors in flavor compositions, as described herein.

[0115] However, the degradation of the flavor in the flavor composition cannot always be completely prevented even with dihydroavenate alkaloid D. Thus, the degradation of the flavor occurs, however only to a lower extent.

[0116] Therefore, a fragrance composition having a peroxide value of at least 0.25 mmol / L has undergone some degree of degradation and therefore does not describe a fragrance composition that is used immediately after its production.

[0117] Preferably, the peroxide value of the fragrance composition can be determined by visual titration. Preferably, for this visual titration method, the sample is treated with acetic acid and a suitable organic solvent (preferably a mixture of acetic acid and a suitable organic solvent), followed by treatment with potassium iodide solution. The generated iodine can then be titrated with a standard sodium thiosulfate solution to determine the peroxide value.

[0118] What was stated above with respect to the use according to the invention or with respect to the process according to the invention applies correspondingly to the fragrance composition according to the invention, in particular with respect to the preferred features.

[0119] It is preferred in the fragrance composition according to the present invention that the composition comprises compound b) in the range of 0.0005 wt.-% to 25 wt.-%, preferably in the range of 0.00075 wt.-% to 22.5 wt.-%, preferably in the range of 0.001 wt.-% to 20 wt.-%, preferably in the range of 0.0025 wt.-% to 17.5 wt.-%, preferably in the range of 0.005 wt.-% to 15 wt.-%, preferably in the range of 0.0075 wt.-% to 12.5 wt.-%, preferably in the range of 0.01 wt.-% to 10 wt.-%, preferably in the range of 0.025 wt.-% to 7.5 wt.-%, preferably in the range of 0.05 wt.-% to 5 wt.-%, based on the total weight of the composition.

[0120] Preferably, for determining the amount of dihydroavenate alkaloid D and / or its salts and / or solvates (i.e. compound b)) in the composition, the total weight of dihydroavenate alkaloid D and its salts and solvates in the composition is taken into account. In the event that one of the above substances is not present in the composition, its weight is considered to be 0 g.

[0121] It is preferred in the fragrance composition according to the invention that the composition comprises compound a) in an amount in the range of 50 wt.-% to 99 wt.-%, preferably 60 wt.-% to 97.5 wt.-%, particularly preferably 70 wt.-% to 95 wt.-%, further preferably 75 wt.-% to 92.5 wt.-%, especially preferably 80 wt.-% to 90 wt.-%, based on the total weight of the composition.

[0122] In the fragrance composition of the present invention, it is preferred that the weight ratio of compound b) to compound a) is in the range of 500:1 to 1:30,000, preferably in the range of 250:1 to 1:10,000, further preferably in the range of 100:1 to 1:1,000, particularly preferably in the range of 10:1 to 1:100, especially preferably in the range of 5:1 to 1:5, even further preferably in the range of 2:1 to 1:2, more preferably in the range of 1.5:1 to 1:1.5.

[0123] In the fragrance composition of the present invention, it is preferred that the one, two, three or more or all fragrances of component a)

[0124] Select the group consisting of Group A.

[0125] It is further preferred that in the fragrance composition of the present invention, the one, two, three or more or all fragrances of component a)

[0126] Select from the group consisting of Group B,

[0127] It is preferably selected from the group consisting of Group C.

[0128] The present invention further relates to cosmetic or pharmaceutical preparations comprising the fragrance composition according to the invention.

[0129] The cosmetic formulations as described herein are in particular formulations suitable for topical application to human skin, in particular to achieve a cosmetic effect.

[0130] Preferably, the pharmaceutical preparation of the present invention is in the form of capsules, tablets (uncoated tablets and coated tablets, for example, with a coating resistant to gastric juice), sugar-coated tablets, granules, pellets, solid mixtures, liquid dispersions, emulsions, powders, solutions, pastes or other swallowable or chewable preparations, and is preferably used as a medicament available only by prescription from a pharmacy or other pharmacy or as a food supplement.

[0131] The cosmetic or pharmaceutical formulations as described herein may further comprise one, two, three or more or all substances selected from the group consisting of: odoriferous substances, essential oils, fatty oils, fatty acids, ceramides, ceramide-like substances, sterols, hydrocarbons, phytosterols, anti-acne active ingredients, anti-dandruff active ingredients, antimicrobial active ingredients, preservatives, antiperspirants, anti-irritants, itch-relieving active ingredients, cooling active ingredients, anti-aging active ingredients, skin lightening and tanning active ingredients, skin moisture regulators, penetrants, insect repellents, enzyme inhibitors, odor absorbers, dyes, abrasives, anti-acne agents, anti-cellulitis agents, anti-dandruff agents, anti-inflammatory agents, anti-irritants, irritation inhibitors, antioxidants, astringents, antiperspirants, antiseptics, agents), antistatic agents, adhesives, buffers, carrier materials, chelating agents, cell stimulants, cleaning agents, conditioning agents, depilatories, surfactants, deodorants, antiperspirants, softeners, emulsifiers, enzymes, essential oils, fibers, film formers, fixatives, foam formers, foam stabilizers, anti-foaming substances, foam boosters, gelling agents, gel-forming agents, hair conditioning agents, hair setting agents, hair straighteners, moisture supply agents, moisturizing substances / moisture-retaining substances), bleaching agents, enhancers, detergents, optical brighteners, impregnants, stain repellents, friction reducers, lubricants, moisturizers, ointments, sunscreens, plasticizers, covering agents, polishes, glosses, polymers, powders, proteins, re-oiling agents, abrasives, silicones, skin soothing agents, skin cleansers, skin care agents, skin healing agents, skin lightening agents, skin protectants, skin softeners, hair growth agents, cooling agents, skin cooling agents, warming agents, skin warming agents, stabilizers, UV absorbers, UV filters, detergents, fabric conditioners, suspending agents, tanning agents, thickeners, vitamins, oils, waxes, fats, phospholipids, saturated fatty acids, monounsaturated or polyunsaturated fatty acids, alpha-hydroxy acids, polyhydroxy fatty acids, liquefiers, dyes, color fixatives, pigments, corrosion inhibitors, fragrances, flavoring substances, odoriferous substances, polyols, surfactants, electrolytes, organic solvents, and silicone derivatives.

[0132] Preferably, the amount of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates in the formulation according to the invention is in the range of 0.0001 wt.-% to 10 wt.-%, preferably in the range of 0.0005 wt.-% to 5 wt.-%, preferably in the range of 0.00075 wt.-% to 2.5 wt.-%, preferably in the range of 0.001 wt.-% to 1 wt.-%, preferably in the range of 0.0025 wt.-% to 0.5, preferably in the range of 0.005 wt.-% to 0.2 wt.-%, preferably in the range of 0.01 wt.-% to 0.1 wt.-%, based on the total weight of the formulation.

[0133] It has surprisingly been found that within these ranges, dihydroavenate alkaloid D and / or salts and / or solvates thereof provide the effects described herein, but also do not provide a glue-like olfactory impression.

[0134] Preferably, for determining the amount of dihydroavenain D and / or its salts and / or solvates in the formulations of the present invention, the total weight of dihydroavenain D and its salts and solvates in the formulation is taken into account. In the event that one of the above substances is not present in the formulation, its weight is considered to be 0 g.

[0135] Preferably, the amount of fragrance(s) in the formulation is in the range of 0.001 wt.-% to 3 wt.-%, preferably 0.005 wt.-% to 2 wt.-%, particularly preferably 0.01 wt.-% to 1.75 wt.-%, further preferably 0.05 wt.-% to 1.5 wt.-%, based on the total weight of the formulation.

[0136] In the formulations of the present invention, it is preferred that the weight ratio of dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates to fragrance(s) is in the range of 500:1 to 1:30,000, preferably in the range of 250:1 to 1:10,000, further preferably in the range of 100:1 to 1:1,000, particularly preferably in the range of 10:1 to 1:100, especially preferably in the range of 5:1 to 1:5, even further preferably in the range of 2:1 to 1:2, and more preferably in the range of 1.5:1 to 1:1.5.

[0137] Preferably, the term "amount of (multiple) spices" refers to the amount selected from the group consisting of Group A,

[0138] Preferably selected from the group consisting of Group B,

[0139] Preferably, a fragrance selected from the group consisting of Group C,

[0140] It is preferred that the total weight of all these spices is taken into account to determine the amount. In the event that a spice is not present in the mixture, its weight is considered to be 0 g.

[0141] Further aspects and advantages of the invention emerge from the subsequent description of preferred embodiments. DETAILED DESCRIPTION

[0142] Example

[0143] Example 1: Fragrance degradation

[0144] A fragrance composition comprising a fragrance was prepared.

[0145]

[0146]

[0147]

[0148] Dihydroavenate alkaloid D was added to the composition to obtain composition A comprising dihydroavenate alkaloid D at a concentration of 0.1 wt.-%.

[0149] Composition A and the same composition but without dihydroavenate alkaloid D (control) were subjected to an artificial ageing process. The artificial ageing process was applied by subjecting the compositions to 70° C. and 5 bar for 24 hours.

[0150] For artificial aging, an ML was designed to monitor oxidation based on oxygen consumption at high temperature and pressure. The samples were aged.

[0151] The sample was weighed into a glass container and placed in a pressure vessel. The vessel was flushed with oxygen and a pressure of 5 bar was applied. The vessel was placed in a block heater and heated to 70°C for 24 hours.

[0152] After the artificial aging process, the composition was analyzed for its components by mass spectrometry (GC-MS) using biphenyl as an internal standard.

[0153] In the composition without dihydroavenate alkaloid D (control), the total amount of the above-mentioned fragrances was reduced to 71% (average value, where 100% is the initial mixed amount).

[0154] In contrast, in the composition containing dihydroavenate alkaloid D, the total amount of the above-mentioned flavors was reduced to only 98% (average value, where 100% is the initial mixed amount).

[0155]

[0156]

[0157] It was surprisingly found that the addition of dihydroavenate alkaloids significantly prevented / reduced the degradation of the flavor in the composition.

[0158] Example 2: Peroxide Value

[0159] A composition comprising the following was prepared,

[0160]

[0161]

[0162] And dihydroavenate alkaloid was added to obtain composition B comprising dihydroavenate alkaloid D at a concentration of 0.1 wt.-%.

[0163] Composition B and the same composition without dihydroavenate alkaloid D (control) were subjected to an artificial aging process as described in Example 1.

[0164] The peroxide value is obtained by treating the corresponding sample with a mixture of acetic acid and a suitable organic solvent and then treating with potassium iodide solution. The generated iodine is titrated with a sodium thiosulfate standard solution to determine the peroxide value.

[0165] The sample (3.0 g) was dissolved in a 3:2 ratio of acetic acid and chloroform (50 mL) in a 250 mL Erlenmeyer flask. Freshly prepared potassium iodide solution (1 mL) was added and the solution was allowed to react for 1 minute while vigorously stirring. Then, distilled water (100 mL) was added and the solution was immediately titrated with sodium thiosulfate solution from a purple color to a slightly yellow or colorless endpoint. A blank titration was performed under the same conditions.

[0166] The consumption from both titrations can be used to calculate the peroxide value.

[0167] The peroxide value of the control was 476.64 mmol / L.

[0168] In contrast, the peroxide value of composition B was 18.06 mmol / L.

[0169] The addition of dihydroavenate alkaloid D to the composition surprisingly resulted in a reduction in the peroxide value after the aging process to only 3% of the peroxide value of the control (ie a 97% reduction).

[0170] Example 3: Peroxide Value

[0171] Preparation of the initial composition of Example 2. A 3% dilution in a neutral oil was prepared to provide a composition representative of a cosmetic composition.

[0172] Dihydroavenate alkaloid was added, obtaining composition C comprising dihydroavenate alkaloid D in a concentration of 0.05 wt.-%.

[0173] Composition C and the same composition but without dihydroavenate alkaloid D (control) were subjected to an artificial aging process as described in Example 1.

[0174] Peroxide value was measured as described in Example 2.

[0175] The peroxide value of the control was 2.57 mmol / L.

[0176] In contrast, the peroxide value of composition C was 1.33 mmol / L.

[0177] The addition of dihydroavenate alkaloid D to the composition surprisingly resulted in a decrease in the peroxide value after the aging process to only 52% of the peroxide value of the control (ie a 48% decrease).

Claims

1. A method of reducing or preventing the degradation of one or more spices comprising: The one or more fragrances are selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers.

2. The use according to claim 1, wherein the one, two, three or more or all fragrances are selected from the group consisting of 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one , (4E)-3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brazilate, and trans-2,cis-6-nonadienal, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethylmethylphenyl glycinate, allyl cyclohexylpropionate, styryl propionate, benzyl salicylate, benzyl ethyl ether, linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyperaldehyde, hydroxycitronellal, lilial and borgihon aldehydes, ionones, isomethyl ionone and methyl cedryl ketone, anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and pine Oleyl alcohol, terpenes, balsam, clary sage oil, chamomile oil, clove oil, lemon balm oil, peppermint oil, cinnamon leaf oil, lime flower oil, juniper oil, vetiver oil, frankincense oil, galbanum oil, labdanum and lavender oils, bergamot oil, dihydromyrcenol, lilial, lyral, phenylethyl alcohol, hexyl cinnamal, benzyl acetone, ambergris, ambroxan, indole, methyl dihydrojasmonate, sandelice, lemon oil, tangerine oil, orange oil, galbanum, cyclovertal, lavender oil, clary sage essential oil, damascena, bourbon geranium essential oil, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldeingamma, phenylacetic acid, geranyl acetate, rose oxide, romillat, irotyl, floramate, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, geranium acid, decanoic acid and its methyl esters, ethyl esters, l-hexen-3-one, l-hepten-3-one, 1-octene-3-one, l-nonen-3-one, l-decen-3-one, octalactone, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 2-ethyl-l-butene, 2-ethyl-l-pentene, 2-ethyl-l-hexene, 2-ethyl-l-heptene, 2-ethyl-l-octene, cis-3-methyl-2-pentene, cis-3-methyl-2-hexene, cis-3-methyl-2 -heptene, cis-3-methyl-2-octene, cis-3-methyl-2-nonene, trans-3-methyl-2-pentene, trans-3-methyl-2-hexene, trans-3-methyl-2-heptene, trans-3-methyl-2-octene, trans-3-methyl-2-nonene, cis-2-hexene, cis-2-heptene, cis-2-octene, cis-2-nonene, cis-2-decene, trans-2-hexene, trans-2-heptene, trans-2-octene, trans-2-nonene, trans-2-decene, cis-3-hexene, cis-3-heptene, cis-3-octene, cis-3-nonene, cis-3-decene, trans-3-hexene, trans-3-heptene, trans-3-octene, trans-3-nonene, trans-3-decene.

3. The use according to any one of the preceding claims, wherein the one, two, three or more or all fragrances are selected from the group consisting of 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one, (4E) -3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brassate, and trans-2, cis-6-nonadienal, Preferably selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, linalool, linalyl acetate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin.

4. Use according to any one of the preceding claims for reducing or preventing degradation in a fragrance composition or a cosmetic or pharmaceutical formulation comprising one or more fragrances, preferably one, two, three or more or all fragrances according to claim 2 or 3.

5. The method according to claim 4 for stabilizing the olfactory impression of the fragrance composition or the cosmetic or pharmaceutical preparation. A reduction in the intensity of the olfactory impression is preferably reduced or prevented.

6. A method for reducing or preventing the degradation of one or more flavors, comprising the following steps: i) selecting one or more flavorants, the degradation of which is to be reduced or prevented, wherein the one, two, three or more or all fragrances are selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers, ii) providing the fragrance selected in step i) iii) providing dihydroavenous alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates iv) mixing the components provided in steps ii) and iii).

7. The method of claim 6, wherein the one, two, three or more or all of the fragrances selected in step i) are selected from the group consisting of 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one , (4E)-3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brazilate, and trans-2,cis-6-nonadienal, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethylmethylphenyl glycinate, allyl cyclohexylpropionate, styryl propionate, benzyl salicylate, benzyl ethyl ether, linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyperaldehyde, hydroxycitronellal, lilial and borgihon aldehydes, ionones, isomethyl ionone and methyl cedryl ketone, anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and pine Oleyl alcohol, terpenes, balsam, clary sage oil, chamomile oil, clove oil, lemon balm oil, peppermint oil, cinnamon leaf oil, lime flower oil, juniper oil, vetiver oil, frankincense oil, galbanum oil, labdanum and lavender oils, bergamot oil, dihydromyrcenol, lilial, lyral, phenylethyl alcohol, hexyl cinnamal, benzyl acetone, ambergris, ambroxan, indole, methyl dihydrojasmonate, sandelice, lemon oil, tangerine oil, orange oil, galbanum esters, cyclovertal, lavender oil, clary sage essential oil, damascena, bourbon geranium essential oil, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, rose oxide, romillat, irotyl, floramate, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, geranium acid, decanoic acid and its methyl esters, ethyl esters, l-hexen-3-one, l-hepten-3-one, 1-octene-3-one, l-nonen-3-one, l-decen-3-one, octalactone, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 2-ethyl-l-butene, 2-ethyl-l-pentene, 2-ethyl-l-hexene, 2-ethyl-l-heptene, 2-ethyl-l-octene, cis-3-methyl-2-pentene, cis-3-methyl-2-hexene, cis-3-methyl-2-heptene, cis-3-methyl 2-octene, cis-3-methyl-2-nonene, trans-3-methyl-2-pentene, trans-3-methyl-2-hexene, trans-3-methyl-2-heptene, trans-3-methyl-2-octene, trans-3-methyl-2-nonene, cis-2-hexene, cis-2-heptene, cis-2-octene, cis-2-nonene, cis-2-decene, trans-2-hexene, trans-2-heptene, trans-2-octene, trans-2-nonene, trans-2-decene, cis-3-hexene, cis-3-heptene, cis-3-octene, cis-3-nonene, cis-3-decene, trans-3-hexene, trans-3-heptene, trans-3-octene, trans-3-nonene, trans-3-decene.

8. The method according to claim 6 or 7, wherein the one, two, three or more or all fragrances are selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one, (4E) -3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brassate, and trans-2, cis-6-nonadienal, Preferably selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, linalool, linalyl acetate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin.

9. A method for stabilizing the olfactory impression of a fragrance composition or a cosmetic preparation or a pharmaceutical preparation, wherein the fragrance composition comprises one, two, three or more or all fragrances selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one , (4E)-3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brazilate, and trans-2,cis-6-nonadienal, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethylmethylphenyl glycinate, allyl cyclohexylpropionate, styryl propionate, benzyl salicylate, benzyl ethyl ether, linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyperaldehyde, hydroxycitronellal, lilial and borgihon aldehydes, ionones, isomethyl ionone and methyl cedryl ketone, anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and pine Oleyl alcohol, terpenes, balsam, clary sage oil, chamomile oil, clove oil, lemon balm oil, peppermint oil, cinnamon leaf oil, lime flower oil, juniper oil, vetiver oil, frankincense oil, galbanum oil, labdanum and lavender oils, bergamot oil, dihydromyrcenol, lilial, lyral, phenylethyl alcohol, hexyl cinnamal, benzyl acetone, ambergris, ambroxan, indole, methyl dihydrojasmonate, sandelice, lemon oil, tangerine oil, orange oil, galbanum esters, cyclovertal, lavender oil, clary sage essential oil, damascena, bourbon geranium essential oil, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, rose oxide, romillat, irotyl, floramate, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, geranium acid, decanoic acid and its methyl esters, ethyl esters, l-hexen-3-one, l-hepten-3-one, 1-octene-3-one, l-nonen-3-one, l-decen-3-one, octalactone, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 2-ethyl-l-butene, 2-ethyl-l-pentene, 2-ethyl-l-hexene, 2-ethyl-l-heptene, 2-ethyl-l-octene, cis-3-methyl-2-pentene, cis-3-methyl-2-hexene, cis-3-methyl-2-heptene, cis-3-methyl 2-octene, cis-3-methyl-2-nonene, trans-3-methyl-2-pentene, trans-3-methyl-2-hexene, trans-3-methyl-2-heptene, trans-3-methyl-2-octene, trans-3-methyl-2-nonene, cis-2-hexene, cis-2-heptene, cis-2-octene, cis-2-nonene, cis-2-decene, trans-2-hexene, trans-2-heptene, trans-2-octene, trans-2-nonene, trans-2-decene, cis-3-hexene, cis-3-heptene, cis-3-octene, cis-3-nonene, cis-3-decene, trans-3-hexene, trans-3-heptene, trans-3-octene, trans-3-nonene, trans-3-decene, The method comprises the following steps a) selecting a fragrance composition or a cosmetic preparation or a pharmaceutical preparation, the degradation of which is to be reduced or prevented, b) providing the fragrance composition or cosmetic preparation or pharmaceutical preparation selected in step a), c) providing dihydroavenous alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates, d) mixing the fragrance composition or cosmetic preparation or pharmaceutical preparation provided in step b) with the dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salt and / or solvate provided in step c).

10. The method according to claim 9, wherein the fragrance composition or cosmetic preparation or pharmaceutical preparation comprises one, two, three or more or all fragrances selected from the group consisting of 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, methyl 2-octynoate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one, (4E) -3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brassate, and trans-2, cis-6-nonadienal, Preferably selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, linalool, linalyl acetate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin.

11. A flavor composition comprising a) one or more fragrances selected from the group consisting of aldehydes, alcohols, esters, ketones or ethers, and b) dihydroavenate alkaloid D and / or its pharmaceutically or cosmetically acceptable salts and / or solvates, wherein the peroxide value of the flavor composition is at least 0.25 mmol / L, preferably at least 0.5 mmol / L, based on the total amount of the flavor composition; And wherein the peroxide value of the fragrance composition is at most 70%, preferably at most 65%, further preferably at most 60%, particularly preferably at most 55% of the peroxide value of the same composition without component b).

12. The flavor composition according to claim 11, wherein the one, two, three or more or all flavors of component a) Selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, 2-octynoic acid methyl ester, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one , (4E)-3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brazilate, and trans-2,cis-6-nonadienal, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohexylpropionate, styryl propionate, benzyl salicylate, benzyl ethyl ether, linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyperaldehyde, hydroxycitronellal, lilial and borgihon aldehydes, ionones, isomethyl ionone and methyl cedryl ketone, anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and pine Oleyl alcohol, terpenes, balsam, clary sage oil, chamomile oil, clove oil, lemon balm oil, peppermint oil, cinnamon leaf oil, lime flower oil, juniper oil, vetiver oil, frankincense oil, galbanum oil, labdanum and lavender oils, bergamot oil, dihydromyrcenol, lilial, lyral, phenylethyl alcohol, hexyl cinnamal, benzyl acetone, ambergris, ambroxan, indole, methyl dihydrojasmonate, sandelice, lemon oil, tangerine oil, orange oil, galbanum, cyclovertal, lavender oil, clary sage essential oil, damascena, bourbon geranium essential oil, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldeingamma, phenylacetic acid, geranyl acetate, rose oxide, romillat, irotyl, floramate, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, geranium acid, decanoic acid and its methyl esters, ethyl esters, l-hexen-3-one, l-hepten-3-one, 1-octene-3-one, l-nonen-3-one, l-decen-3-one, octalactone, 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 2-ethyl-l-butene, 2-ethyl-l-pentene, 2-ethyl-l-hexene, 2-ethyl-l-heptene, 2-ethyl-l-octene, cis-3-methyl-2-pentene, cis-3-methyl-2-hexene, cis-3-methyl-2 -heptene, cis-3-methyl-2-octene, cis-3-methyl-2-nonene, trans-3-methyl-2-pentene, trans-3-methyl-2-hexene, trans-3-methyl-2-heptene, trans-3-methyl-2-octene, trans-3-methyl-2-nonene, cis-2-hexene, cis-2-heptene, cis-2-octene, cis-2-nonene, cis-2-decene, trans-2-hexene, trans-2-heptene, trans-2-octene, trans-2-nonene, trans-2-decene, cis-3-hexene, cis-3-heptene, cis-3-octene, cis-3-nonene, cis-3-decene, trans-3-hexene, trans-3-heptene, trans-3-octene, trans-3-nonene, trans-3-decene.

13. The flavor composition according to claim 11 or 12, wherein the one, two, three or more or all flavors of component a) Selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, ethyl acetoacetate, (Z)-hex-3-en-1-yl methyl carbonate, linalool, linalyl acetate, cyclohexanol, 2-(1,1-dimethylethyl)-acetate, 2-octynoic acid methyl ester, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, (ethoxymethoxy)cyclododecane, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, γ-undecalactone, cis-3-hexenyl salicylate, pentadecanolactone, (5E)-3-methyl-5-cyclopentadecen-1-one, 3-methyl-5-cyclopentadecen-1-one, (4E) -3-methyl-4-cyclopentadecen-1-one, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, oxocycloheptadecan-10-en-2-one, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin, ethylene glycol brassate, and trans-2, cis-6-nonadienal, Preferably selected from the group consisting of: 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, linalool, linalyl acetate, (2E)-3,7-dimethylocta-2,6-dienal, 3,7-dimethyloct-6-en-1-ol, 2,6,10-trimethylundec-9-enal, 3-(o-ethylphenyl)-2,2-dimethylpropanal and 3-(p-ethylphenyl)-2,2-dimethylpropanal, hydroxycitronellal, silybdate, anisaldehyde, Iso E Gamma, (2E)-2-ethyl-4-(2,2,3)-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta(g)-2-benzopyran, α-hexylcinnamaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, ethyl vanillin, vanillin.

14. A cosmetic or pharmaceutical preparation comprising the fragrance composition according to any one of claims 11 to 13.

Images